We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Tool Helps See How Cells Work Together Inside Diseased Tissue

By LabMedica International staff writers
Posted on 16 Feb 2026

Microscopes have long been central to diagnosing disease by allowing doctors to examine stained tissue samples. More...

However, modern medical research now generates vast amounts of additional data, including detailed maps of gene and protein activity within cells. These diverse data types are difficult to interpret together, limiting a full understanding of how diseases develop and progress. A new artificial intelligence (AI) system now brings these data streams into a unified framework, offering a more comprehensive picture of tissue biology and disease.

Researchers at Yale University (New Haven, CT, USA); have developed a computational platform called spEMO, short for spatial multi-modal embeddings, designed to integrate tissue images with molecular and biological information. The system uses Pathology Foundation Models trained on large datasets to interpret images, language-based biological knowledge, and molecular signals. By merging these models into a shared analytical space, spEMO enables coordinated analysis of tissue structure, gene expression, and protein activity.

Researchers demonstrated that spEMO could more accurately distinguish distinct regions within tissues and predict disease states compared with methods relying on a single data type. The system also identified communication patterns between cells and helped generate draft medical reports that integrated visual and genetic information. In evaluations by expert pathologists, AI-generated reports were considered more complete and accurate than those based solely on images. The findings, published in Nature Biomedical Engineering, highlight the potential of multimodal AI in biomedical research.

Using cancer datasets as a case example, the platform identified potential interactions between immune cells within tumors by combining tissue images with predicted gene activity. Such insights may improve understanding of tumor biology and treatment responses. Although still under refinement, the researchers suggest the system could accelerate research, support diagnostic workflows, and contribute to personalized medicine. By integrating multiple biological signals, the technology offers a more holistic approach to disease analysis.

“This approach moves us closer to a more holistic view of disease,” said Dr. Hongyu Zhao, PhD, the study’s senior author and a professor of biostatistics at the Yale School of Public Health. “By bringing together molecular data and tissue structure, we can gain insights that would otherwise be missed.”

Related Links:
Yale University


New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.